Palatin's pre-IND oral MC4R agonist faces a long road to proof-of-concept in obesity and rare disorders against a field dominated by approved GLP-1 agents

Palatin Technologies is an early-stage company developing an oral targeted obesity drug that is not yet approved, aimed at general obesity and rare genetic disorders including Prader-Willi syndrome and Bardet-Biedl syndrome.

Palatin is developing a next-generation oral MC4R selective agonist targeting general obesity and rare disorders including Prader-Willi syndrome and Bardet-Biedl syndrome, with an IND not yet submitted. The thesis depends entirely on whether first-in-human data demonstrate meaningful clinical efficacy differentiating MC4R agonism from GLP-1 dominance. The primary risks are the entrenched approvals of semaglutide and tirzepatide and the mixed clinical history of MC4R agonism, with setmelanotide's narrow label illustrating the bar for rare-disease differentiation.